oncotomskСибирский онкологический журналSiberian journal of oncology1814-48612312-3168Tomsk National Research Medical Сепtеr of the Russian Academy of Sciences10.21294/1814-4861-2022-21-3-104-116oncotomsk-2168Research ArticleОБЗОРЫREVIEWSРоль жидкостной биопсии в диагностике прогрессирования глиобластомыThe role of liquid biopsy in the diagnosis of glioblastoma progressionhttps://orcid.org/0000-0002-7171-8728РябоваА. И.RyabovaA. I.

Рябова Анастасия Игоревна, кандидат медицинских наук, старший научный сотрудник

634009, г. Томск, пер. Кооперативный, 5

Anastasiya I. Ryabova, MD, PhD, Senior Researcher, Cancer Research Institute

5, Kooperativny Street, 634009, Tomsk

Bochkarevanv@oncology.tomsk.ruhttps://orcid.org/0000-0003-0364-0831НовиковВ. А.NovikovV. A.

Новиков Валерий Александрович, доктор медицинских наук, ведущий научный сотрудник; доцент кафедры онкологии

634009, г. Томск, пер. Кооперативный, 5; 634050, г. Томск, Московский тракт, 2

Valery A. Novikov, MD, DSc, Leading Researcher

5, Kooperativny Street, 634009, Tomsk; 2, Moskovsky tract, 634050, Tomsk

https://orcid.org/0000-0002-3651-0665ЧойнзоновЕ. Л.ChoynzonovE. L.

Чойнзонов Евгений Лхамацыренович, доктор медицинских наук, профессор, академик РАН, директор; заведующий кафедрой онкологии

634009, г. Томск, пер. Кооперативный, 5; 634050, г. Томск, Московский тракт, 2

Evgeny L. Choynzonov, MD, DSc, Professor, Member of the Russian Academy of Sciences

5, Kooperativny Street, 634009, Tomsk; 2, Moskovsky tract, 634050, Tomsk

https://orcid.org/0000-0002-5269-736XСпиринаЛ. В.SpirinaL. V.

Спирина Людмила Викторовна, доктор медицинских наук, ведущий научный сотрудник, Научно-исследовательский институт онкологии; исполняющий обязанности заведующей кафедрой биохимии и молекулярной биологии с курсом клинической лабораторной диагностики

634009, г. Томск, пер. Кооперативный, 5; 634050, г. Томск, Московский тракт, 2

Lyudmila V. Spirina, MD, DSc, Leading Researcher

5, Kooperativny Street, 634009, Tomsk; 2, Moskovsky tract, 634050, Tomsk

https://orcid.org/0000-0003-4595-4177ЮнусоваН. В.YunusovaN. V.

Юнусова Наталья Валерьевна, доктор медицинских наук, ведущий научный сотрудник, Научно-исследовательский институт онкологии; профессор кафедры биохимии и молекулярной биологии с курсом клинической лабораторной диагностики

634009, г. Томск, пер. Кооперативный, 5; 634050, г. Томск, Московский тракт, 2

Natalia V. Yunusova, MD, DSc

5, Kooperativny Street, 634009, Tomsk; 2, Moskovsky tract, 634050, Tomsk

https://orcid.org/0000-0003-2060-4840ПономареваА. А.PonomarevaA. A.

Пономарёва Анастасия Алексеевна, кандидат биологических наук, старший научный сотрудник

634009, г. Томск, пер. Кооперативный, 5

Anastasiya A. Ponomaryova, PhD

5, Kooperativny Street, 634009, Tomsk

ТамковичС. Н.TamkovichS. N.

Тамкович Светлана Николаевна, кандидат биологических наук, старший научный сотрудник лаборатории молекулярной медицины; доцент кафедры клинической биохимии

630090, г. Новосибирск, пр. Академика Лаврентьева, 8; 630090, г. Новосибирск, ул. Пирогова, 2

Svetlana N. Tamkovich, PhD, Senior Researcher

8, Academician Lavrentiev Ave., 630090, Novosibirsk; 2, Pirogova St., 630090, Novosibirsk

https://orcid.org/0000-0003-1696-427XГрибоваО. В.GribovaO. V.

Грибова Ольга Вячеславовна, доктор медицинских наук, старший научный сотрудник

634009, г. Томск, пер. Кооперативный, 5

Olga V. Gribova, MD, DSc, Senior Researcher

5, Kooperativny Street, 634009, Tomsk

Научно-исследовательский институт онкологии, Томский национальный исследовательский медицинский центр Российской академии наукРоссияCancer Research Institute, Tomsk National Research Medical Center, Russian Academy of SciencesRussian FederationНаучно-исследовательский институт онкологии, Томский национальный исследовательский медицинский центр Российской академии наук; ФГБОУ ВО «Сибирский государственный медицинский университет» Минздрава РоссииРоссияCancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences; Siberian State Medical University of the Ministry of Health of RussiaRussian FederationЛаборатория молекулярной медицины Института химической биологии и фундаментальной медицины СО РАН; Кафедра клинической биохимии, ФГБОУ ВО «Новосибирский национальный исследовательский государственный университет»РоссияSiberian Branch of Russian Academy of Sciences; Department of Clinical Biochemistry, Novosibirsk State UniversityRussian Federation202229062022213104116Copyright © Рябова А.И., Новиков В.А., Чойнзонов Е.Л., Спирина Л.В., Юнусова Н.В., Пономарева А.А., Тамкович С.Н., Грибова О.В., 20222022Рябова А.И., Новиков В.А., Чойнзонов Е.Л., Спирина Л.В., Юнусова Н.В., Пономарева А.А., Тамкович С.Н., Грибова О.В.Ryabova A.I., Novikov V.A., Choynzonov E.L., Spirina L.V., Yunusova N.V., Ponomareva A.A., Tamkovich S.N., Gribova O.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.siboncoj.ru/jour/article/view/2168

Цель исследования – обобщение имеющихся данных о диагностической ценности различных циркулирующих биомаркеров для диагностики рецидива глиобластомы.

Материал и методы

Материал и методы. Проведен биоинформациооный поиск в универсальной базе данных PubMED, в базе данных экзосомальных белков, РНК и липидов ExoCarta, в базе данных внеклеточной ДНК, в базе данных внеклеточной ДНК SILVA.

Результаты

Результаты. Мультиформная глиобластома (МГБ) – наиболее распространенная глиальная опухоль у взрослых с плачевным прогнозом. Лечение рецидива опухоли может улучшить выживаемость пациентов. Нейровизуализация – стандартный метод диагностики рецидива опухоли головного мозга. Однако методы нейровизуализации, позволяющие четко различать прогрессирование опухоли и связанные с лечением рентгенографические изменения на ранних стадиях, сегодня не найдены. Современное молекулярное профилирование опухоли в значительной степени зависит от резекции ткани или биопсии. Профилирование ткани имеет несколько недостатков при опухолях центральной нервной системы, в т. ч. проблемы, связанные с инвазивной биопсией, неоднородной природой многих злокачественных новообразований, когда небольшая биопсия может недооценивать мутационный профиль. Жидкая биопсия – перспективное направление современной онкологии. Сбор крови – это простая, малоинвазивная процедура, но спинномозговая жидкость позволяет более уверенно обнаруживать опухолевые маркеры, однако получение ее является сложной и инвазивной процедурой, которая может сопровождаться серьезными осложнениями.

Заключение

Заключение. Маркеры биологических жидкостей, такие как циркулирующие опухолевые клетки, внеклеточные везикулы, внеклеточная ДНК и внеклеточная РНК, позволяют выявить МГБ, определить молекулярно-генетические особенности рака во время ответа на терапию и обнаружить рецидив МГБ на ранней стадии.

Purpose

Purpose: to summarize available data on the diagnostic value of various circulating biomarkers for the detection of glioblastoma recurrence.

Material and Methods

Material and Methods. A literature search was conducted using PubMED ExoCarta and SILVA databases.

Results

Results. Glioblastoma multiforme (GBM) is the most common glioma in adults with an unfavorable prognosis. Treatment of tumor recurrence can improve the survival of patients. Neuroimaging is the standard method of diagnosing brain tumor recurrence. However, a neuroimaging method to clearly distinguish between pseudo progression and tumor progression has not been found to date. Current molecular tumor profling relies heavily on tissue resection or biopsy. Tissue profling has several disadvantages in the central nervous system’s tumors, including the challenge associated with invasive biopsy, the heterogeneous nature of many malignancies where a small biopsy can under represent the mutational profle. Liquid biopsy is a promising method in diagnosing malignant tumors. Blood collection is a simple, minimally invasive procedure, but cerebrospinal fuid allows tumor markers to be detected more confdently. However, collection of cerebrospinal fuid is a complex and invasive procedure that can be accompanied by serious complications.

Conclusion

Conclusion. Biological fuid markers such as circulating tumor cells, extracellular vesicles, cell-free DNA and cell-free RNA allow for the detection of GMB, determination of molecular genetic features of cancer during response to therapy, and early detection of GBM recurrence.

внеклеточные везикулывнеклеточная ДНКвнеклеточная РНКциркулирующие опухолевые клеткирецидив глиобластомыдиагностика опухолейextracellular vesiclescell-free DNAcell-free RNAcirculating tumor cellsglioblastoma recurrencetumor diagnosticsReferencesOstrom Q.T., Cioff G., Gittleman H., Patil N., Waite K., Kruchko C., Barnholtz-Sloan J.S. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012–2016. Neuro Oncol. 2019; 21(5):1–100. doi: 10.1093/neuonc/noz150.Ostrom Q.T., Cioff G., Gittleman H., Patil N., Waite K., Kruchko C., Barnholtz-Sloan J.S. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012–2016. Neuro Oncol. 2019; 21(5):1–100. doi: 10.1093/neuonc/noz150.Chinot O.L., Wick W., Mason W., Henriksson R., Saran F., Nishikawa R., Carpentier A.F., Hoang-Xuan K., Kavan P., Cernea D., Brandes A.A., Hilton M., Abrey L., Cloughesy T. Bevacizumab plus radiotherapytemozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014; 370(8): 709–22. doi: 10.1056/NEJMoa1308345.Chinot O.L., Wick W., Mason W., Henriksson R., Saran F., Nishikawa R., Carpentier A.F., Hoang-Xuan K., Kavan P., Cernea D., Brandes A.A., Hilton M., Abrey L., Cloughesy T. Bevacizumab plus radiotherapytemozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014; 370(8): 709–22. doi: 10.1056/NEJMoa1308345.Gilbert M.R., Dignam J.J., Armstrong T.S., Wefel J.S., Blumenthal D.T., Vogelbaum M.A., Colman H., Chakravarti A., Pugh S., Won M., Jeraj R., Brown P.D., Jaeckle K.A., Schiff D., Stieber V.W., Brachman D.G., WernerWasik M., Tremont-Lukats I.W., Sulman E.P., Aldape K.D., Curran W.J. Jr., Mehta M.P. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014; 370(8): 699–708. doi: 10.1056/NEJMoa1308573.Gilbert M.R., Dignam J.J., Armstrong T.S., Wefel J.S., Blumenthal D.T., Vogelbaum M.A., Colman H., Chakravarti A., Pugh S., Won M., Jeraj R., Brown P.D., Jaeckle K.A., Schiff D., Stieber V.W., Brachman D.G., WernerWasik M., Tremont-Lukats I.W., Sulman E.P., Aldape K.D., Curran W.J. Jr., Mehta M.P. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014; 370(8): 699–708. doi: 10.1056/NEJMoa1308573.Stupp R., Taillibert S., Kanner A., Read W., Steinberg D., Lhermitte B., Toms S., Idbaih A., Ahluwalia M.S., Fink K., Di Meco F., Lieberman F., Zhu J.J., Stragliotto G., Tran D., Brem S., Hottinger A., Kirson E.D., Lavy-Shahaf G., Weinberg U., Kim C.Y., Paek S.H., Nicholas G., Bruna J., Hirte H., Weller M., Palti Y., Hegi M.E., Ram Z. Efect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial. JAMA. 2017; 318(23): 2306–16. doi: 10.1001/jama.2017.18718.Stupp R., Taillibert S., Kanner A., Read W., Steinberg D., Lhermitte B., Toms S., Idbaih A., Ahluwalia M.S., Fink K., Di Meco F., Lieberman F., Zhu J.J., Stragliotto G., Tran D., Brem S., Hottinger A., Kirson E.D., Lavy-Shahaf G., Weinberg U., Kim C.Y., Paek S.H., Nicholas G., Bruna J., Hirte H., Weller M., Palti Y., Hegi M.E., Ram Z. Efect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial. JAMA. 2017; 318(23): 2306–16. doi: 10.1001/jama.2017.18718.Louis D.N., Perry A., Reifenberger G., von Deimling A., FigarellaBranger D., Cavenee W.K., Ohgaki H., Wiestler O.D., Kleihues P., Ellison D.W. The 2016 World Health Organization Classifcation of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016; 131(6): 803–20. doi: 10.1007/s00401-016-1545-1.Louis D.N., Perry A., Reifenberger G., von Deimling A., FigarellaBranger D., Cavenee W.K., Ohgaki H., Wiestler O.D., Kleihues P., Ellison D.W. The 2016 World Health Organization Classifcation of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016; 131(6): 803–20. doi: 10.1007/s00401-016-1545-1.Soffetti R., Franchino F., Magistrello M., Pellerino A., Rudà R. Perspectives of Personalized Chemotherapy of Gliomas Based on Molecular Tumor Profling. Prog Neurol Surg. 2018; 31: 168–79. doi: 10.1159/000467378.Soffetti R., Franchino F., Magistrello M., Pellerino A., Rudà R. Perspectives of Personalized Chemotherapy of Gliomas Based on Molecular Tumor Profling. Prog Neurol Surg. 2018; 31: 168–79. doi: 10.1159/000467378.Weller M., Le Rhun E., Preusser M., Tonn J.C., Roth P. How we treat glioblastoma. ESMO Open. 2019; 4(2). doi: 10.1136/esmoopen-2019-000520.Weller M., Le Rhun E., Preusser M., Tonn J.C., Roth P. How we treat glioblastoma. ESMO Open. 2019; 4(2). doi: 10.1136/esmoopen-2019-000520.Strauss S.B., Meng A., Ebani E.J., Chiang G.C. Imaging Glioblastoma Posttreatment: Progression, Pseudoprogression, Pseudoresponse, Radiation Necrosis. Radiol Clin North Am. 2019; 57(6): 1199–216. doi: 10.1016/j.rcl.2019.07.003.Strauss S.B., Meng A., Ebani E.J., Chiang G.C. Imaging Glioblastoma Posttreatment: Progression, Pseudoprogression, Pseudoresponse, Radiation Necrosis. Radiol Clin North Am. 2019; 57(6): 1199–216. doi: 10.1016/j.rcl.2019.07.003.Arevalo O.D., Soto C., Rabiei P., Kamali A., Ballester L.Y., Esquenazi Y., Zhu J.J., Riascos R.F. Assessment of Glioblastoma Response in the Era of Bevacizumab: Longstanding and Emergent Challenges in the Imaging Evaluation of Pseudoresponse. Front Neurol. 2019; 10: 460. doi: 10.3389/fneur.2019.00460.Arevalo O.D., Soto C., Rabiei P., Kamali A., Ballester L.Y., Esquenazi Y., Zhu J.J., Riascos R.F. Assessment of Glioblastoma Response in the Era of Bevacizumab: Longstanding and Emergent Challenges in the Imaging Evaluation of Pseudoresponse. Front Neurol. 2019; 10: 460. doi: 10.3389/fneur.2019.00460.Zikou A., Sioka C., Alexiou G.A., Fotopoulos A., Voulgaris S., Argyropoulou M.I. Radiation Necrosis, Pseudoprogression, Pseudoresponse, and Tumor Recurrence: Imaging Challenges for the Evaluation of Treated Gliomas. Contrast Media Mol Imaging. 2018; 2018: 6828396. doi: 10.1155/2018/6828396.Zikou A., Sioka C., Alexiou G.A., Fotopoulos A., Voulgaris S., Argyropoulou M.I. Radiation Necrosis, Pseudoprogression, Pseudoresponse, and Tumor Recurrence: Imaging Challenges for the Evaluation of Treated Gliomas. Contrast Media Mol Imaging. 2018; 2018: 6828396. doi: 10.1155/2018/6828396.Macarthur K.M., Kao G.D., Chandrasekaran S., Alonso-Basanta M., Chapman C., Lustig R.A., Wileyto E.P., Hahn S.M., Dorsey J.F. Detection of brain tumor cells in the peripheral blood by a telomerase promoter-based assay. Cancer Res. 2014; 74(8): 2152–9. doi: 10.1158/0008-5472.CAN-13-0813.Macarthur K.M., Kao G.D., Chandrasekaran S., Alonso-Basanta M., Chapman C., Lustig R.A., Wileyto E.P., Hahn S.M., Dorsey J.F. Detection of brain tumor cells in the peripheral blood by a telomerase promoter-based assay. Cancer Res. 2014; 74(8): 2152–9. doi: 10.1158/0008-5472.CAN-13-0813.Gao F., Cui Y., Jiang H., Sui D., Wang Y., Jiang Z., Zhao J., Lin S. Circulating tumor cell is a common property of brain glioma and promotes the monitoring system. Oncotarget. 2016; 7(44): 71330–40. doi: 10.18632/oncotarget.11114.Gao F., Cui Y., Jiang H., Sui D., Wang Y., Jiang Z., Zhao J., Lin S. Circulating tumor cell is a common property of brain glioma and promotes the monitoring system. Oncotarget. 2016; 7(44): 71330–40. doi: 10.18632/oncotarget.11114.Mohammadi H., Shiue K., Grass G.D., Verma V., Engellandt K., Daubner D., Schackert G., Gondim M.J., Gondim D., Vortmeyer A.O., Kamer A.P., William J., Robinson T.J., Watson G., Yu H.H.M., Lautenschlaeger T. Isocitrate dehydrogenase 1 mutant glioblastomas demonstrate a decreased rate of pseudoprogression: a multi-institutional experience. Neurooncol Pract. 2020; 7(2): 185–95. doi: 10.1093/nop/npz050.Mohammadi H., Shiue K., Grass G.D., Verma V., Engellandt K., Daubner D., Schackert G., Gondim M.J., Gondim D., Vortmeyer A.O., Kamer A.P., William J., Robinson T.J., Watson G., Yu H.H.M., Lautenschlaeger T. Isocitrate dehydrogenase 1 mutant glioblastomas demonstrate a decreased rate of pseudoprogression: a multi-institutional experience. Neurooncol Pract. 2020; 7(2): 185–95. doi: 10.1093/nop/npz050.Sottoriva A., Spiteri I., Piccirillo S.G., Touloumis A., Collins V.P., Marioni J.C., Curtis C., Watts C., Tavaré S. Intratumor heterogeneity in human glioblastoma refects cancer evolutionary dynamics. Proc Natl Acad Sci USA. 2013; 110(10): 4009–14. doi: 10.1073/pnas.1219747110.Sottoriva A., Spiteri I., Piccirillo S.G., Touloumis A., Collins V.P., Marioni J.C., Curtis C., Watts C., Tavaré S. Intratumor heterogeneity in human glioblastoma refects cancer evolutionary dynamics. Proc Natl Acad Sci USA. 2013; 110(10): 4009–14. doi: 10.1073/pnas.1219747110.Draaisma K., Chatzipli A., Taphoorn M., Kerkhof M., Weyerbrock A., Sanson M., Hoeben A., Lukacova S., Lombardi G., Leenstra S., Hanse M., Fleischeuer R., Watts C., McAbee J., Angelopoulos N., Gorlia T., Golfnopoulos V., Kros J.M., Verhaak R.G.W., Bours V., van den Bent M.J., McDermott U., Robe P.A., French P.J. Molecular Evolution of IDH WildType Glioblastomas Treated With Standard of Care Afects Survival and Design of Precision Medicine Trials: A Report From the EORTC 1542 Study. J Clin Oncol. 2020; 38(1): 81–99. doi: 10.1200/JCO.19.00367.Draaisma K., Chatzipli A., Taphoorn M., Kerkhof M., Weyerbrock A., Sanson M., Hoeben A., Lukacova S., Lombardi G., Leenstra S., Hanse M., Fleischeuer R., Watts C., McAbee J., Angelopoulos N., Gorlia T., Golfnopoulos V., Kros J.M., Verhaak R.G.W., Bours V., van den Bent M.J., McDermott U., Robe P.A., French P.J. Molecular Evolution of IDH WildType Glioblastomas Treated With Standard of Care Afects Survival and Design of Precision Medicine Trials: A Report From the EORTC 1542 Study. J Clin Oncol. 2020; 38(1): 81–99. doi: 10.1200/JCO.19.00367.García-Romero N., Carrión-Navarro J., Esteban-Rubio S., Lázaro-Ibáñez E., Peris-Celda M., Alonso M.M., Guzmán-De-Villoria J., Fernández-Carballal C., de Mendivil A.O., García-Duque S., EscobedoLucea C., Prat-Acín R., Belda-Iniesta C., Ayuso-Sacido A. DNA sequences within glioma-derived extracellular vesicles can cross the intact blood-brain barrier and be detected in peripheral blood of patients. Oncotarget. 2017; 8(1): 1416–28. doi: 10.18632/oncotarget.13635.García-Romero N., Carrión-Navarro J., Esteban-Rubio S., Lázaro-Ibáñez E., Peris-Celda M., Alonso M.M., Guzmán-De-Villoria J., Fernández-Carballal C., de Mendivil A.O., García-Duque S., EscobedoLucea C., Prat-Acín R., Belda-Iniesta C., Ayuso-Sacido A. DNA sequences within glioma-derived extracellular vesicles can cross the intact blood-brain barrier and be detected in peripheral blood of patients. Oncotarget. 2017; 8(1): 1416–28. doi: 10.18632/oncotarget.13635.Shankar G.M., Balaj L., Stott S.L., Nahed B., Carter B.S. Liquid biopsy for brain tumors. Expert Rev Mol Diagn. 2017; 17(10): 943–7. doi: 10.1080/14737159.2017.1374854.Shankar G.M., Balaj L., Stott S.L., Nahed B., Carter B.S. Liquid biopsy for brain tumors. Expert Rev Mol Diagn. 2017; 17(10): 943–7. doi: 10.1080/14737159.2017.1374854.Müller Bark J., Kulasinghe A., Chua B., Day B.W., Punyadeera C. Circulating biomarkers in patients with glioblastoma. Br J Cancer. 2020; 122(3): 295–305. doi: 10.1038/s41416-019-0603-6.Müller Bark J., Kulasinghe A., Chua B., Day B.W., Punyadeera C. Circulating biomarkers in patients with glioblastoma. Br J Cancer. 2020; 122(3): 295–305. doi: 10.1038/s41416-019-0603-6.Silantyev A.S., Falzone L., Libra M., Gurina O.I., Kardashova K.S., Nikolouzakis T.K., Nosyrev A.E., Sutton C.W., Mitsias P.D., Tsatsakis A. Current and Future Trends on Diagnosis and Prognosis of Glioblastoma: From Molecular Biology to Proteomics. Cells. 2019; 8(8): 863. doi: 10.3390/cells8080863.Silantyev A.S., Falzone L., Libra M., Gurina O.I., Kardashova K.S., Nikolouzakis T.K., Nosyrev A.E., Sutton C.W., Mitsias P.D., Tsatsakis A. Current and Future Trends on Diagnosis and Prognosis of Glioblastoma: From Molecular Biology to Proteomics. Cells. 2019; 8(8): 863. doi: 10.3390/cells8080863.Quddusi A., Shamim M.S. Serum biomarkers for glioblastoma multiforme. J Pak Med Assoc. 2019; 69(6): 913–4.Quddusi A., Shamim M.S. Serum biomarkers for glioblastoma multiforme. J Pak Med Assoc. 2019; 69(6): 913–4.Figueroa J.M., Skog J., Akers J., Li H., Komotar R., Jensen R., Ringel F., Yang I., Kalkanis S., Thompson R., LoGuidice L., Berghoff E., Parsa A., Liau L., Curry W., Cahill D., Bettegowda C., Lang F.F., Chiocca E.A., Henson J., Kim R., Breakefeld X., Chen C., Messer K., Hochberg F., Carter B.S. Detection of wild-type EGFR amplifcation and EGFRvIII mutation in CSF-derived extracellular vesicles of glioblastoma patients. Neuro Oncol. 2017; 19(11): 1494–1502. doi: 10.1093/neuonc/nox085.Figueroa J.M., Skog J., Akers J., Li H., Komotar R., Jensen R., Ringel F., Yang I., Kalkanis S., Thompson R., LoGuidice L., Berghoff E., Parsa A., Liau L., Curry W., Cahill D., Bettegowda C., Lang F.F., Chiocca E.A., Henson J., Kim R., Breakefeld X., Chen C., Messer K., Hochberg F., Carter B.S. Detection of wild-type EGFR amplifcation and EGFRvIII mutation in CSF-derived extracellular vesicles of glioblastoma patients. Neuro Oncol. 2017; 19(11): 1494–1502. doi: 10.1093/neuonc/nox085.Lee J.S., Melisko M.E., Magbanua M.J., Kablanian A.T., Scott J.H., Rugo H.S., Park J.W. Detection of cerebrospinal fuid tumor cells and its clinical relevance in leptomeningeal metastasis of breast cancer. Breast Cancer Res Treat. 2015; 154(2): 339–49. doi: 10.1007/s10549-015-3610-1.Lee J.S., Melisko M.E., Magbanua M.J., Kablanian A.T., Scott J.H., Rugo H.S., Park J.W. Detection of cerebrospinal fuid tumor cells and its clinical relevance in leptomeningeal metastasis of breast cancer. Breast Cancer Res Treat. 2015; 154(2): 339–49. doi: 10.1007/s10549-015-3610-1.Malani R., Fleisher M., Kumthekar P., Lin X., Omuro A., Groves M.D., Lin N.U., Melisko M., Lassman A.B., Jeyapalan S., Seidman A., Skakodub A., Boire A., DeAngelis L.M., Rosenblum M., Raizer J., Pentsova E. Cerebrospinal fuid circulating tumor cells as a quantifable measurement of leptomeningeal metastases in patients with HER2 positive cancer. J Neurooncol. 2020; 148(3): 599–606. doi: 10.1007/s11060-020-03555-z.Malani R., Fleisher M., Kumthekar P., Lin X., Omuro A., Groves M.D., Lin N.U., Melisko M., Lassman A.B., Jeyapalan S., Seidman A., Skakodub A., Boire A., DeAngelis L.M., Rosenblum M., Raizer J., Pentsova E. Cerebrospinal fuid circulating tumor cells as a quantifable measurement of leptomeningeal metastases in patients with HER2 positive cancer. J Neurooncol. 2020; 148(3): 599–606. doi: 10.1007/s11060-020-03555-z.Katz R.L., Zaidi T.M., Ni X. Liquid Biopsy: Recent Advances in the Detection of Circulating Tumor Cells and Their Clinical Applications. In: Bui MM, Pantanowitz L (eds). Modern Techniques in Cytopathology. Monogr Clin Cytol. Basel, Karger. 2020; 25: 43–66. doi: 10.1159/000455780.Katz R.L., Zaidi T.M., Ni X. Liquid Biopsy: Recent Advances in the Detection of Circulating Tumor Cells and Their Clinical Applications. In: Bui MM, Pantanowitz L (eds). Modern Techniques in Cytopathology. Monogr Clin Cytol. Basel, Karger. 2020; 25: 43–66. doi: 10.1159/000455780.Müller C., Holtschmidt J., Auer M., Heitzer E., Lamszus K., Schulte A., Matschke J., Langer-Freitag S., Gasch C., Stoupiec M., Mauermann O., Peine S., Glatzel M., Speicher M.R., Geigl J.B., Westphal M., Pantel K., Riethdorf S. Hematogenous dissemination of glioblastoma multiforme. Sci Transl Med. 2014; 6(247). doi: 10.1126/scitranslmed.3009095.Müller C., Holtschmidt J., Auer M., Heitzer E., Lamszus K., Schulte A., Matschke J., Langer-Freitag S., Gasch C., Stoupiec M., Mauermann O., Peine S., Glatzel M., Speicher M.R., Geigl J.B., Westphal M., Pantel K., Riethdorf S. Hematogenous dissemination of glioblastoma multiforme. Sci Transl Med. 2014; 6(247). doi: 10.1126/scitranslmed.3009095.Carvalho J.A.D.V., Barbosa C.C.L., Feher O., Maldaun M.V.C., Camargo V.P., Moraes F.Y., Marta G.N. Systemic dissemination of glioblastoma: literature review. Rev Assoc Med Bras (1992). 2019; 65(3): 460–8. doi: 10.1590/1806-9282.65.3.460.Carvalho J.A.D.V., Barbosa C.C.L., Feher O., Maldaun M.V.C., Camargo V.P., Moraes F.Y., Marta G.N. Systemic dissemination of glioblastoma: literature review. Rev Assoc Med Bras (1992). 2019; 65(3): 460–8. doi: 10.1590/1806-9282.65.3.460.Böhm C., Wassmann H., Paulus W. No evidence of tumour cells in blood of patients with glioma. Mol Pathol. 2003; 56(3): 187–9. doi: 10.1136/mp.56.3.187.Böhm C., Wassmann H., Paulus W. No evidence of tumour cells in blood of patients with glioma. Mol Pathol. 2003; 56(3): 187–9. doi: 10.1136/mp.56.3.187.Sullivan J.P., Nahed B.V., Madden M.W., Oliveira S.M., Springer S., Bhere D., Chi A.S., Wakimoto H., Rothenberg S.M., Sequist L.V., Kapur R., Shah K., Iafrate A.J., Curry W.T., Loeffer J.S., Batchelor T.T., Louis D.N., Toner M., Maheswaran S., Haber D.A. Brain tumor cells in circulation are enriched for mesenchymal gene expression. Cancer Discov. 2014; 4(11): 1299–309. doi: 10.1158/2159-8290.CD-14-0471.Sullivan J.P., Nahed B.V., Madden M.W., Oliveira S.M., Springer S., Bhere D., Chi A.S., Wakimoto H., Rothenberg S.M., Sequist L.V., Kapur R., Shah K., Iafrate A.J., Curry W.T., Loeffer J.S., Batchelor T.T., Louis D.N., Toner M., Maheswaran S., Haber D.A. Brain tumor cells in circulation are enriched for mesenchymal gene expression. Cancer Discov. 2014; 4(11): 1299–309. doi: 10.1158/2159-8290.CD-14-0471.Kolostova K., Pospisilova E., Pavlickova V., Bartos R., Sames M., Pawlak I., Bobek V. Next generation sequencing of glioblastoma circulating tumor cells: non-invasive solution for disease monitoring. Am J Transl Res. 2021; 13(5): 4489–99.Kolostova K., Pospisilova E., Pavlickova V., Bartos R., Sames M., Pawlak I., Bobek V. Next generation sequencing of glioblastoma circulating tumor cells: non-invasive solution for disease monitoring. Am J Transl Res. 2021; 13(5): 4489–99.Hallal S., Ebrahimkhani S., Shivalingam B., Graeber M.B., Kaufman K.L., Buckland M.E. The emerging clinical potential of circulating extracellular vesicles for non-invasive glioma diagnosis and disease monitoring. Brain Tumor Pathol. 2019; 36(2): 29–39. doi: 10.1007/s10014-019-00335-0.Hallal S., Ebrahimkhani S., Shivalingam B., Graeber M.B., Kaufman K.L., Buckland M.E. The emerging clinical potential of circulating extracellular vesicles for non-invasive glioma diagnosis and disease monitoring. Brain Tumor Pathol. 2019; 36(2): 29–39. doi: 10.1007/s10014-019-00335-0.Chen W.W., Balaj L., Liau L.M., Samuels M.L., Kotsopoulos S.K., Maguire C.A., Loguidice L., Soto H., Garrett M., Zhu L.D., Sivaraman S., Chen C., Wong E.T., Carter B.S., Hochberg F.H., Breakefield X.O., Skog J. BEAMing and Droplet Digital PCR Analysis of Mutant IDH1 mRNA in Glioma Patient Serum and Cerebrospinal Fluid Extracellular Vesicles. Mol Ther Nucleic Acids. 2013; 2(7): 109. doi: 10.1038/mtna.2013.28.Chen W.W., Balaj L., Liau L.M., Samuels M.L., Kotsopoulos S.K., Maguire C.A., Loguidice L., Soto H., Garrett M., Zhu L.D., Sivaraman S., Chen C., Wong E.T., Carter B.S., Hochberg F.H., Breakefield X.O., Skog J. BEAMing and Droplet Digital PCR Analysis of Mutant IDH1 mRNA in Glioma Patient Serum and Cerebrospinal Fluid Extracellular Vesicles. Mol Ther Nucleic Acids. 2013; 2(7): 109. doi: 10.1038/mtna.2013.28.Lane R., Simon T., Vintu M., Solkin B., Koch B., Stewart N., Benstead-Hume G., Pearl F.M.G., Critchley G., Stebbing J., Giamas G. Cell-derived extracellular vesicles can be used as a biomarker reservoir for glioblastoma tumor subtyping. Commun Biol. 2019; 2: 315. doi: 10.1038/s42003-019-0560-x.Lane R., Simon T., Vintu M., Solkin B., Koch B., Stewart N., Benstead-Hume G., Pearl F.M.G., Critchley G., Stebbing J., Giamas G. Cell-derived extracellular vesicles can be used as a biomarker reservoir for glioblastoma tumor subtyping. Commun Biol. 2019; 2: 315. doi: 10.1038/s42003-019-0560-x.Wang H., Jiang D., Li W., Xiang X., Zhao J., Yu B., Wang C., He Z., Zhu L., Yang Y. Evaluation of serum extracellular vesicles as noninvasive diagnostic markers of glioma. Theranostics. 2019; 9(18): 5347–58.Wang H., Jiang D., Li W., Xiang X., Zhao J., Yu B., Wang C., He Z., Zhu L., Yang Y. Evaluation of serum extracellular vesicles as noninvasive diagnostic markers of glioma. Theranostics. 2019; 9(18): 5347–58.Morishita M., Takahashi Y., Nishikawa M., Takakura Y. Pharmacokinetics of Exosomes-An Important Factor for Elucidating the Biological Roles of Exosomes and for the Development of ExosomeBased Therapeutics. J Pharm Sci. 2017; 106(9): 2265–9. doi: 10.1016/j.xphs.2017.02.030.Morishita M., Takahashi Y., Nishikawa M., Takakura Y. Pharmacokinetics of Exosomes-An Important Factor for Elucidating the Biological Roles of Exosomes and for the Development of ExosomeBased Therapeutics. J Pharm Sci. 2017; 106(9): 2265–9. doi: 10.1016/j.xphs.2017.02.030.Tamkovich S.N., Yunusova N.V., Stakheeva М.N., Somov A.K., Frolova А.Y., Kirushina N.А., Afanasyev S.G., Grigoryeva А.E,. Laktionov P.P., Kondakova I.V. Isolation and characterization of exosomes from blood plasma of breast cancer and colorectal cancer patients. Biomed Khim. 2017; 63(2):165–9. doi: 10.18097/PBMC20176302165.Tamkovich S.N., Yunusova N.V., Stakheeva М.N., Somov A.K., Frolova А.Y., Kirushina N.А., Afanasyev S.G., Grigoryeva А.E,. Laktionov P.P., Kondakova I.V. Isolation and characterization of exosomes from blood plasma of breast cancer and colorectal cancer patients. Biomed Khim. 2017; 63(2):165–9. doi: 10.18097/PBMC20176302165.Ciccocioppo F., Lanuti P., Marchisio M., Miscia S. Extracellular Vesicles Involvement in the Modulation of the Glioblastoma Environment. J Oncol. 2020; 2020: 3961735. doi: 10.1155/2020/3961735.Ciccocioppo F., Lanuti P., Marchisio M., Miscia S. Extracellular Vesicles Involvement in the Modulation of the Glioblastoma Environment. J Oncol. 2020; 2020: 3961735. doi: 10.1155/2020/3961735.Yekula A., Yekula A., Muralidharan K., Kang K., Carter B.S., Balaj L. Extracellular Vesicles in Glioblastoma Tumor Microenvironment. Front Immunol. 2020; 10: 3137. doi: 10.3389/fmmu.2019.03137.Yekula A., Yekula A., Muralidharan K., Kang K., Carter B.S., Balaj L. Extracellular Vesicles in Glioblastoma Tumor Microenvironment. Front Immunol. 2020; 10: 3137. doi: 10.3389/fmmu.2019.03137.André-Grégoire G., Bidère N., Gavard J. Temozolomide afects Extracellular Vesicles Released by Glioblastoma Cells. Biochimie. 2018; 155: 11–5. doi: 10.1016/j.biochi.2018.02.007.André-Grégoire G., Bidère N., Gavard J. Temozolomide afects Extracellular Vesicles Released by Glioblastoma Cells. Biochimie. 2018; 155: 11–5. doi: 10.1016/j.biochi.2018.02.007.Osti D., Del Bene M., Rappa G., Santos M., Matafora V., Richichi C., Faletti S., Beznoussenko G.V., Mironov A., Bachi A., Fornasari L., Bongetta D., Gaetani P., DiMeco F., Lorico A., Pelicci G. Clinical Signifcance of Extracellular Vesicles in Plasma from Glioblastoma Patients. Clin Cancer Res. 2019; 25(1): 266–76. doi: 10.1158/1078-0432.CCR18-1941.Osti D., Del Bene M., Rappa G., Santos M., Matafora V., Richichi C., Faletti S., Beznoussenko G.V., Mironov A., Bachi A., Fornasari L., Bongetta D., Gaetani P., DiMeco F., Lorico A., Pelicci G. Clinical Signifcance of Extracellular Vesicles in Plasma from Glioblastoma Patients. Clin Cancer Res. 2019; 25(1): 266–76. doi: 10.1158/1078-0432.CCR18-1941.Evans S.M., Putt M., Yang X.Y., Lustig R.A., Martinez-Lage M., Williams D., Desai A., Wolf R., Brem S., Koch C.J. Initial evidence that blood-borne microvesicles are biomarkers for recurrence and survival in newly diagnosed glioblastoma patients. J Neurooncol. 2016; 127(2): 391–400. doi: 10.1007/s11060-015-2051-3.Evans S.M., Putt M., Yang X.Y., Lustig R.A., Martinez-Lage M., Williams D., Desai A., Wolf R., Brem S., Koch C.J. Initial evidence that blood-borne microvesicles are biomarkers for recurrence and survival in newly diagnosed glioblastoma patients. J Neurooncol. 2016; 127(2): 391–400. doi: 10.1007/s11060-015-2051-3.Koch C.J., Lustig R.A., Yang X.Y., Jenkins W.T., Wolf R.L., Martinez-Lage M., Desai A., Williams D., Evans S.M. Microvesicles as a Biomarker for Tumor Progression versus Treatment Efect in Radiation/ Temozolomide-Treated Glioblastoma Patients. Transl Oncol. 2014; 7(6): 752–8. doi: 10.1016/j.tranon.2014.10.004.Koch C.J., Lustig R.A., Yang X.Y., Jenkins W.T., Wolf R.L., Martinez-Lage M., Desai A., Williams D., Evans S.M. Microvesicles as a Biomarker for Tumor Progression versus Treatment Efect in Radiation/ Temozolomide-Treated Glioblastoma Patients. Transl Oncol. 2014; 7(6): 752–8. doi: 10.1016/j.tranon.2014.10.004.Shao H., Chung J., Balaj L., Charest A., Bigner D.D., Carter B.S., Hochberg F.H., Breakefeld X.O., Weissleder R., Lee H. Protein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapy. Nat Med. 2012; 18(12): 1835–40. doi: 10.1038/nm.2994.Shao H., Chung J., Balaj L., Charest A., Bigner D.D., Carter B.S., Hochberg F.H., Breakefeld X.O., Weissleder R., Lee H. Protein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapy. Nat Med. 2012; 18(12): 1835–40. doi: 10.1038/nm.2994.Akers J.C., Ramakrishnan V., Kim R., Skog J., Nakano I., Pingle S., Kalinina J., Hua W., Kesari S., Mao Y., Breakefeld X.O., Hochberg F.H., Van Meir E.G., Carter B.S., Chen C.C. MiR-21 in the extracellular vesicles (EVs) of cerebrospinal fuid (CSF): a platform for glioblastoma biomarker development. PLoS One. 2013; 8(10): 78115. doi: 10.1371/journal.pone.0078115.Akers J.C., Ramakrishnan V., Kim R., Skog J., Nakano I., Pingle S., Kalinina J., Hua W., Kesari S., Mao Y., Breakefeld X.O., Hochberg F.H., Van Meir E.G., Carter B.S., Chen C.C. MiR-21 in the extracellular vesicles (EVs) of cerebrospinal fuid (CSF): a platform for glioblastoma biomarker development. PLoS One. 2013; 8(10): 78115. doi: 10.1371/journal.pone.0078115.Ebrahimkhani S., Vafaee F., Hallal S., Wei H., Lee M.Y.T., Young P.E., Satgunaseelan L., Beadnall H., Barnett M.H., Shivalingam B., Suter C.M., Buckland M.E., Kaufman K.L. Deep sequencing of circulating exosomal microRNA allows non-invasive glioblastoma diagnosis. NPJ Precis Oncol. 2018; 2: 28. doi: 10.1038/s41698-018-0071-0.Ebrahimkhani S., Vafaee F., Hallal S., Wei H., Lee M.Y.T., Young P.E., Satgunaseelan L., Beadnall H., Barnett M.H., Shivalingam B., Suter C.M., Buckland M.E., Kaufman K.L. Deep sequencing of circulating exosomal microRNA allows non-invasive glioblastoma diagnosis. NPJ Precis Oncol. 2018; 2: 28. doi: 10.1038/s41698-018-0071-0.Jafari D., Tiyuri A., Rezaei E., Moradi Y., Jafari R., Jokar Shoorijeh F., Barati M. Diagnostic accuracy of cerebrospinal fuid and serum-isolated extracellular vesicles for glioblastoma: a systematic review and meta-analysis. Expert Rev Mol Diagn. 2020; 20(11): 1075–85. doi: 10.1080/14737159.2020.1844006.Jafari D., Tiyuri A., Rezaei E., Moradi Y., Jafari R., Jokar Shoorijeh F., Barati M. Diagnostic accuracy of cerebrospinal fuid and serum-isolated extracellular vesicles for glioblastoma: a systematic review and meta-analysis. Expert Rev Mol Diagn. 2020; 20(11): 1075–85. doi: 10.1080/14737159.2020.1844006.Santangelo A., Imbrucè P., Gardenghi B., Belli L., Agushi R., Tamanini A., Munari S., Bossi A.M., Scambi I., Benati D., Mariotti R., Di Gennaro G., Sbarbati A., Eccher A., Ricciardi G.K., Ciceri E.M., Sala F., Pinna G., Lippi G., Cabrini G., Dechecchi M.C. A microRNA signature from serum exosomes of patients with glioma as complementary diagnostic biomarker. J Neurooncol. 2018; 136(1): 51–62. doi: 10.1007/s11060-017-2639-x.Santangelo A., Imbrucè P., Gardenghi B., Belli L., Agushi R., Tamanini A., Munari S., Bossi A.M., Scambi I., Benati D., Mariotti R., Di Gennaro G., Sbarbati A., Eccher A., Ricciardi G.K., Ciceri E.M., Sala F., Pinna G., Lippi G., Cabrini G., Dechecchi M.C. A microRNA signature from serum exosomes of patients with glioma as complementary diagnostic biomarker. J Neurooncol. 2018; 136(1): 51–62. doi: 10.1007/s11060-017-2639-x.Lan F., Qing Q., Pan Q., Hu M., Yu H., Yue X. Serum exosomal miR-301a as a potential diagnostic and prognostic biomarker for human glioma. Cell Oncol (Dordr). 2018; 41(1): 25–33. doi: 10.1007/s13402-017-0355-3.Lan F., Qing Q., Pan Q., Hu M., Yu H., Yue X. Serum exosomal miR-301a as a potential diagnostic and prognostic biomarker for human glioma. Cell Oncol (Dordr). 2018; 41(1): 25–33. doi: 10.1007/s13402-017-0355-3.Lan F., Yue X., Xia T. Exosomal microRNA-210 is a potentially non-invasive biomarker for the diagnosis and prognosis of glioma. Oncol Lett. 2020; 19(3): 1967–74. doi: 10.3892/ol.2020.11249.Lan F., Yue X., Xia T. Exosomal microRNA-210 is a potentially non-invasive biomarker for the diagnosis and prognosis of glioma. Oncol Lett. 2020; 19(3): 1967–74. doi: 10.3892/ol.2020.11249.Galbo P.M. Jr., Ciesielski M.J., Figel S., Maguire O., Qiu J., Wiltsie L., Minderman H., Fenstermaker R.A. Circulating CD9+/GFAP+/survivin+ exosomes in malignant glioma patients following survivin vaccination. Oncotarget. 2017; 8(70): 114722–35. doi: 10.18632/oncotarget.21773.Galbo P.M. Jr., Ciesielski M.J., Figel S., Maguire O., Qiu J., Wiltsie L., Minderman H., Fenstermaker R.A. Circulating CD9+/GFAP+/survivin+ exosomes in malignant glioma patients following survivin vaccination. Oncotarget. 2017; 8(70): 114722–35. doi: 10.18632/oncotarget.21773.Lv S., Dai C., Liu Y., Shi R., Tang Z., Han M., Bian R., Sun B., Wang R. Retraction Note to: The Impact of Survivin on Prognosis and Clinicopathology of Glioma Patients: A Systematic Meta-Analysis. Mol Neurobiol. 2017; 54(3): 2376. doi: 10.1007/s12035-017-0402-0.Lv S., Dai C., Liu Y., Shi R., Tang Z., Han M., Bian R., Sun B., Wang R. Retraction Note to: The Impact of Survivin on Prognosis and Clinicopathology of Glioma Patients: A Systematic Meta-Analysis. Mol Neurobiol. 2017; 54(3): 2376. doi: 10.1007/s12035-017-0402-0.Brennan K., Martin K., FitzGerald S.P., O’Sullivan J., Wu Y., Blanco A., Richardson C., Mc Gee M.M. A comparison of methods for the isolation and separation of extracellular vesicles from protein and lipid particles in human serum. Sci Rep. 2020. doi: https://doi.org/10.1038/s41598-020-57497-7.Brennan K., Martin K., FitzGerald S.P., O’Sullivan J., Wu Y., Blanco A., Richardson C., Mc Gee M.M. A comparison of methods for the isolation and separation of extracellular vesicles from protein and lipid particles in human serum. Sci Rep. 2020. doi: https://doi.org/10.1038/s41598-020-57497-7.Tamkovich S., Bryzgunova O. Protease Activity and CellFree DNA in Blood Plasma of Healthy Donors and Breast Cancer Patients. J Immunoassay Immunochem. 2016; 37(2): 141–53. doi: 10.1080/15321819.2015.1069745.Tamkovich S., Bryzgunova O. Protease Activity and CellFree DNA in Blood Plasma of Healthy Donors and Breast Cancer Patients. J Immunoassay Immunochem. 2016; 37(2): 141–53. doi: 10.1080/15321819.2015.1069745.Bryzgunova O.E., Tamkovich S.N., Cherepanova A.V., Yarmoshchuk S.V., Permyakova V.I., Anykeeva O.Y., Laktionov P.P. Redistribution of Free- and Cell-Surface-Bound DNA in Blood of Benign and Malignant Prostate Tumor Patients. Acta Naturae. 2015; 7(2): 115–8.Bryzgunova O.E., Tamkovich S.N., Cherepanova A.V., Yarmoshchuk S.V., Permyakova V.I., Anykeeva O.Y., Laktionov P.P. Redistribution of Free- and Cell-Surface-Bound DNA in Blood of Benign and Malignant Prostate Tumor Patients. Acta Naturae. 2015; 7(2): 115–8.Bagley S.J., Nabavizadeh S.A., Mays J.J., Till J.E., Ware J.B., Levy S., Sarchiapone W., Hussain J., Prior T., Guiry S., Christensen T., Yee S.S., Nasrallah M.P., Morrissette J.J.D., Binder Z.A., O’Rourke D.M., Cucchiara A.J., Brem S., Desai A.S., Carpenter E.L. Clinical Utility of Plasma Cell-Free DNA in Adult Patients with Newly Diagnosed Glioblastoma: A Pilot Prospective Study. Clin Cancer Res. 2020; 26(2): 397–407. doi: 10.1158/1078-0432.CCR-19-2533.Bagley S.J., Nabavizadeh S.A., Mays J.J., Till J.E., Ware J.B., Levy S., Sarchiapone W., Hussain J., Prior T., Guiry S., Christensen T., Yee S.S., Nasrallah M.P., Morrissette J.J.D., Binder Z.A., O’Rourke D.M., Cucchiara A.J., Brem S., Desai A.S., Carpenter E.L. Clinical Utility of Plasma Cell-Free DNA in Adult Patients with Newly Diagnosed Glioblastoma: A Pilot Prospective Study. Clin Cancer Res. 2020; 26(2): 397–407. doi: 10.1158/1078-0432.CCR-19-2533.Nørøxe D.S., Østrup O., Yde C.W., Ahlborn L.B., Nielsen F.C., Michaelsen S.R., Larsen V.A., Skjøth-Rasmussen J., Brennum J., Hamerlik P., Poulsen H.S., Lassen U. Cell-free DNA in newly diagnosed patients with glioblastoma – a clinical prospective feasibility study. Oncotarget. 2019; 10(43): 4397–4406. doi: 10.18632/oncotarget.27030.Nørøxe D.S., Østrup O., Yde C.W., Ahlborn L.B., Nielsen F.C., Michaelsen S.R., Larsen V.A., Skjøth-Rasmussen J., Brennum J., Hamerlik P., Poulsen H.S., Lassen U. Cell-free DNA in newly diagnosed patients with glioblastoma – a clinical prospective feasibility study. Oncotarget. 2019; 10(43): 4397–4406. doi: 10.18632/oncotarget.27030.Duvvuri B., Lood C. Cell-Free DNA as a Biomarker in Autoimmune Rheumatic Diseases. Front Immunol. 2019; 10: 502. doi: 10.3389/fmmu.2019.00502.Duvvuri B., Lood C. Cell-Free DNA as a Biomarker in Autoimmune Rheumatic Diseases. Front Immunol. 2019; 10: 502. doi: 10.3389/fmmu.2019.00502.Hou Y.Q., Liang D.Y., Lou X.L., Zhang M., Zhang Z.H., Zhang L.R. Branched DNA-based Alu quantitative assay for cell-free plasma DNA levels in patients with sepsis or systemic infammatory response syndrome. J Crit Care. 2016; 31(1): 90–5. doi: 10.1016/j.jcrc.2015.10.013.Hou Y.Q., Liang D.Y., Lou X.L., Zhang M., Zhang Z.H., Zhang L.R. Branched DNA-based Alu quantitative assay for cell-free plasma DNA levels in patients with sepsis or systemic infammatory response syndrome. J Crit Care. 2016; 31(1): 90–5. doi: 10.1016/j.jcrc.2015.10.013.Jing R., Cui M., Wang H., Ju S. Cell-free DNA: characteristics, detection and its applications in myocardial infarction. Curr Pharm Des. 2013; 19(28): 5135–45. doi: 10.2174/1381612811319280012.Jing R., Cui M., Wang H., Ju S. Cell-free DNA: characteristics, detection and its applications in myocardial infarction. Curr Pharm Des. 2013; 19(28): 5135–45. doi: 10.2174/1381612811319280012.Balaña C., Ramirez J.L., Taron M., Roussos Y., Ariza A., Ballester R., Sarries C., Mendez P., Sanchez J.J., Rosell R. O6-methyl-guanine-DNA methyltransferase methylation in serum and tumor DNA predicts response to 1,3-bis(2-chloroethyl)-1-nitrosourea but not to temozolamide plus cisplatin in glioblastoma multiforme. Clin Cancer Res. 2003; 9(4): 1461–8.Balaña C., Ramirez J.L., Taron M., Roussos Y., Ariza A., Ballester R., Sarries C., Mendez P., Sanchez J.J., Rosell R. O6-methyl-guanine-DNA methyltransferase methylation in serum and tumor DNA predicts response to 1,3-bis(2-chloroethyl)-1-nitrosourea but not to temozolamide plus cisplatin in glioblastoma multiforme. Clin Cancer Res. 2003; 9(4): 1461–8.Weaver K.D., Grossman S.A., Herman J.G. Methylated tumorspecifc DNA as a plasma biomarker in patients with glioma. Cancer Invest. 2006; 24(1): 35–40. doi: 10.1080/07357900500449546.Weaver K.D., Grossman S.A., Herman J.G. Methylated tumorspecifc DNA as a plasma biomarker in patients with glioma. Cancer Invest. 2006; 24(1): 35–40. doi: 10.1080/07357900500449546.Majchrzak-Celińska A., Paluszczak J., Kleszcz R., Magiera M., Barciszewska A.M., Nowak S., Baer-Dubowska W. Detection of MGMT, RASSF1A, p15INK4B, and p14ARF promoter methylation in circulating tumor-derived DNA of central nervous system cancer patients. J Appl Genet. 2013; 54(3): 335–44. doi: 10.1007/s13353-013-0149-x.Majchrzak-Celińska A., Paluszczak J., Kleszcz R., Magiera M., Barciszewska A.M., Nowak S., Baer-Dubowska W. Detection of MGMT, RASSF1A, p15INK4B, and p14ARF promoter methylation in circulating tumor-derived DNA of central nervous system cancer patients. J Appl Genet. 2013; 54(3): 335–44. doi: 10.1007/s13353-013-0149-x.Lavon I., Refael M., Zelikovitch B., Shalom E., Siegal T. Serum DNA can defne tumor-specifc genetic and epigenetic markers in gliomas of various grades. Neuro Oncol. 2010; 12(2): 173–80. doi: 10.1093/neuonc/nop041.Lavon I., Refael M., Zelikovitch B., Shalom E., Siegal T. Serum DNA can defne tumor-specifc genetic and epigenetic markers in gliomas of various grades. Neuro Oncol. 2010; 12(2): 173–80. doi: 10.1093/neuonc/nop041.Boisselier B., Gállego Pérez-Larraya J., Rossetto M., Labussière M., Ciccarino P., Marie Y., Delattre J.Y., Sanson M. Detection of IDH1 mutation in the plasma of patients with glioma. Neurology. 2012; 79(16): 1693–8. doi: 10.1212/WNL.0b013e31826e9b0a.Boisselier B., Gállego Pérez-Larraya J., Rossetto M., Labussière M., Ciccarino P., Marie Y., Delattre J.Y., Sanson M. Detection of IDH1 mutation in the plasma of patients with glioma. Neurology. 2012; 79(16): 1693–8. doi: 10.1212/WNL.0b013e31826e9b0a.Salkeni M.A., Zarzour A., Ansay T.Y., McPherson C.M., Warnick R.E., Rixe O., Bahassi el M. Detection of EGFRvIII mutant DNA in the peripheral blood of brain tumor patients. J Neurooncol. 2013; 115(1): 27–35. doi: 10.1007/s11060-013-1209-0.Salkeni M.A., Zarzour A., Ansay T.Y., McPherson C.M., Warnick R.E., Rixe O., Bahassi el M. Detection of EGFRvIII mutant DNA in the peripheral blood of brain tumor patients. J Neurooncol. 2013; 115(1): 27–35. doi: 10.1007/s11060-013-1209-0.Bettegowda C., Sausen M., Leary R.J., Kinde I., Wang Y., Agrawal N., Bartlett B.R., Wang H., Luber B., Alani R.M., Antonarakis E.S., Azad N.S., Bardelli A., Brem H., Cameron J.L., Lee C.C., Fecher L.A., Gallia G.L., Gibbs P., Le D., Giuntoli R.L., Goggins M., Hogarty M.D., Holdhoff M., Hong S.M., Jiao Y., Juhl H.H., Kim J.J., Siravegna G., Laheru D.A., Lauricella C., Lim M., Lipson E.J., Marie S.K., Netto G.J., Oliner K.S., Olivi A., Olsson L., Riggins G.J., Sartore-Bianchi A., Schmidt K., Shih l.M., Oba-Shinjo S.M., Siena S., Theodorescu D., Tie J., Harkins T.T., Veronese S., Wang T.L., Weingart J.D., Wolfgang C.L., Wood L.D., Xing D., Hruban R.H., Wu J., Allen P.J., Schmidt C.M., Choti M.A., Velculescu V.E., Kinzler K.W., Vogelstein B., Papadopoulos N., Diaz L.A. Jr. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014; 6(224). doi: 10.1126/scitranslmed.3007094.Bettegowda C., Sausen M., Leary R.J., Kinde I., Wang Y., Agrawal N., Bartlett B.R., Wang H., Luber B., Alani R.M., Antonarakis E.S., Azad N.S., Bardelli A., Brem H., Cameron J.L., Lee C.C., Fecher L.A., Gallia G.L., Gibbs P., Le D., Giuntoli R.L., Goggins M., Hogarty M.D., Holdhoff M., Hong S.M., Jiao Y., Juhl H.H., Kim J.J., Siravegna G., Laheru D.A., Lauricella C., Lim M., Lipson E.J., Marie S.K., Netto G.J., Oliner K.S., Olivi A., Olsson L., Riggins G.J., Sartore-Bianchi A., Schmidt K., Shih l.M., Oba-Shinjo S.M., Siena S., Theodorescu D., Tie J., Harkins T.T., Veronese S., Wang T.L., Weingart J.D., Wolfgang C.L., Wood L.D., Xing D., Hruban R.H., Wu J., Allen P.J., Schmidt C.M., Choti M.A., Velculescu V.E., Kinzler K.W., Vogelstein B., Papadopoulos N., Diaz L.A. Jr. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014; 6(224). doi: 10.1126/scitranslmed.3007094.Schwaederle M., Husain H., Fanta P.T., Piccioni D.E., Kesari S., Schwab R.B., Banks K.C., Lanman R.B., Talasaz A., Parker B.A., Kurzrock R. Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay. Oncotarget. 2016; 7(9): 9707–17. doi: 10.18632/oncotarget.7110.Schwaederle M., Husain H., Fanta P.T., Piccioni D.E., Kesari S., Schwab R.B., Banks K.C., Lanman R.B., Talasaz A., Parker B.A., Kurzrock R. Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay. Oncotarget. 2016; 7(9): 9707–17. doi: 10.18632/oncotarget.7110.Piccioni D.E., Achrol A.S., Kiedrowski L.A., Banks K.C., Boucher N., Barkhoudarian G., Kelly D.F., Juarez T., Lanman R.B., Raymond V.M., Nguyen M., Truong J.D., Heng A., Gill J., Saria M., Pingle S.C., Kesari S. Analysis of cell-free circulating tumor DNA in 419 patients with glioblastoma and other primary brain tumors. CNS Oncol. 2019; 8(2). doi: 10.2217/cns-2018-0015.Piccioni D.E., Achrol A.S., Kiedrowski L.A., Banks K.C., Boucher N., Barkhoudarian G., Kelly D.F., Juarez T., Lanman R.B., Raymond V.M., Nguyen M., Truong J.D., Heng A., Gill J., Saria M., Pingle S.C., Kesari S. Analysis of cell-free circulating tumor DNA in 419 patients with glioblastoma and other primary brain tumors. CNS Oncol. 2019; 8(2). doi: 10.2217/cns-2018-0015.Ahmed K.I., Govardhan H.B., Roy M., Naveen T., Siddanna P., Sridhar P., Suma M.N., Nelson N. Cell-free circulating tumor DNA in patients with high-grade glioma as diagnostic biomarker – A guide to future directive. Indian J Cancer. 2019; 56(1): 65–9. doi: 10.4103/ijc.IJC_551_17.Ahmed K.I., Govardhan H.B., Roy M., Naveen T., Siddanna P., Sridhar P., Suma M.N., Nelson N. Cell-free circulating tumor DNA in patients with high-grade glioma as diagnostic biomarker – A guide to future directive. Indian J Cancer. 2019; 56(1): 65–9. doi: 10.4103/ijc.IJC_551_17.Wang Z., Jiang W., Wang Y., Guo Y., Cong Z., Du F., Song B. MGMT promoter methylation in serum and cerebrospinal fuid as a tumor-specifc biomarker of glioma. Biomed Rep. 3(4) (2015), 543-548.Wang Z., Jiang W., Wang Y., Guo Y., Cong Z., Du F., Song B. MGMT promoter methylation in serum and cerebrospinal fuid as a tumor-specifc biomarker of glioma. Biomed Rep. 3(4) (2015), 543-548.Wang Y., Springer S., Zhang M., McMahon K.W., Kinde I., Dobbyn L., Ptak J., Brem H., Chaichana K., Gallia G.L., Gokaslan Z.L., Groves M.L., Jallo G.I., Lim M., Olivi A., Quinones-Hinojosa A., Rigamonti D., Riggins G.J., Sciubba D.M., Weingart J.D., Wolinsky J.P., Ye X., Oba-Shinjo S.M., Marie S.K., Holdhoff M., Agrawal N., Diaz L.A. Jr., Papadopoulos N., Kinzler K.W., Vogelstein B., Bettegowda C. Detection of tumor-derived DNA in cerebrospinal fuid of patients with primary tumors of the brain and spinal cord. Proc Natl Acad Sci USA. 2015; 112(31): 9704–9. doi: 10.1073/pnas.1511694112.Wang Y., Springer S., Zhang M., McMahon K.W., Kinde I., Dobbyn L., Ptak J., Brem H., Chaichana K., Gallia G.L., Gokaslan Z.L., Groves M.L., Jallo G.I., Lim M., Olivi A., Quinones-Hinojosa A., Rigamonti D., Riggins G.J., Sciubba D.M., Weingart J.D., Wolinsky J.P., Ye X., Oba-Shinjo S.M., Marie S.K., Holdhoff M., Agrawal N., Diaz L.A. Jr., Papadopoulos N., Kinzler K.W., Vogelstein B., Bettegowda C. Detection of tumor-derived DNA in cerebrospinal fuid of patients with primary tumors of the brain and spinal cord. Proc Natl Acad Sci USA. 2015; 112(31): 9704–9. doi: 10.1073/pnas.1511694112.Osei E., Walters P., Masella O., Tennant Q., Fishwick A., Dadzie E., Bhangu A., Darko J. A review of predictive, prognostic and diagnostic biomarkers for brain tumours: Towards personalised and targeted cancer therapy. J Radiother Pract. 2019; 1–16.Osei E., Walters P., Masella O., Tennant Q., Fishwick A., Dadzie E., Bhangu A., Darko J. A review of predictive, prognostic and diagnostic biomarkers for brain tumours: Towards personalised and targeted cancer therapy. J Radiother Pract. 2019; 1–16.Rhodes C.H., Honsinger C., Sorenson G.D. PCR-detection of tumor-derived p53 DNA in cerebrospinal fuid. Am J Clin Pathol. 1995; 103(4): 404–8. doi: 10.1093/ajcp/103.4.404.Rhodes C.H., Honsinger C., Sorenson G.D. PCR-detection of tumor-derived p53 DNA in cerebrospinal fuid. Am J Clin Pathol. 1995; 103(4): 404–8. doi: 10.1093/ajcp/103.4.404.De Mattos-Arruda L., Mayor R., Ng C.K.Y., Weigelt B., MartínezRicarte F., Torrejon D., Oliveira M., Arias A., Raventos C., Tang J., Guerini-Rocco E., Martínez-Sáez E., Lois S., Marín O., de la Cruz X., Piscuoglio S., Towers R., Vivancos A., Peg V., Ramon y Cajal S., Carles J., Rodon J., González-Cao M., Tabernero J., Felip E., Sahuquillo J., Berger M.F., Cortes J., Reis-Filho J.S., Seoane J. Cerebrospinal fuidderived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. Nat Commun. 2015; 6: 8839. doi: 10.1038/ncomms9839.De Mattos-Arruda L., Mayor R., Ng C.K.Y., Weigelt B., MartínezRicarte F., Torrejon D., Oliveira M., Arias A., Raventos C., Tang J., Guerini-Rocco E., Martínez-Sáez E., Lois S., Marín O., de la Cruz X., Piscuoglio S., Towers R., Vivancos A., Peg V., Ramon y Cajal S., Carles J., Rodon J., González-Cao M., Tabernero J., Felip E., Sahuquillo J., Berger M.F., Cortes J., Reis-Filho J.S., Seoane J. Cerebrospinal fuidderived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. Nat Commun. 2015; 6: 8839. doi: 10.1038/ncomms9839.Miller A.M., Shah R.H., Pentsova E.I., Pourmaleki M., Briggs S., Distefano N., Zheng Y., Skakodub A., Mehta S.A., Campos C., Hsieh W.Y., Selcuklu S.D., Ling L., Meng F., Jing X., Samoila A., Bale T.A., Tsui D.W.Y., Grommes C., Viale A., Souweidane M.M., Tabar V., Brennan C.W., Reiner A.S., Rosenblum M., Panageas K.S., DeAngelis L.M., Young R.J., Berger M.F., Mellinghoff I.K. Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fuid. Nature. 2019; 565(7741): 654–8. doi: 10.1038/s41586-019-0882-3.Miller A.M., Shah R.H., Pentsova E.I., Pourmaleki M., Briggs S., Distefano N., Zheng Y., Skakodub A., Mehta S.A., Campos C., Hsieh W.Y., Selcuklu S.D., Ling L., Meng F., Jing X., Samoila A., Bale T.A., Tsui D.W.Y., Grommes C., Viale A., Souweidane M.M., Tabar V., Brennan C.W., Reiner A.S., Rosenblum M., Panageas K.S., DeAngelis L.M., Young R.J., Berger M.F., Mellinghoff I.K. Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fuid. Nature. 2019; 565(7741): 654–8. doi: 10.1038/s41586-019-0882-3.Day G.S., Rappai T., Sathyan S., Morris J.C. Deciphering the factors that infuence participation in studies requiring serial lumbar punctures. Alzheimers Dement (Amst). 2020; 12(1). doi: 10.1002/dad2.12003.Day G.S., Rappai T., Sathyan S., Morris J.C. Deciphering the factors that infuence participation in studies requiring serial lumbar punctures. Alzheimers Dement (Amst). 2020; 12(1). doi: 10.1002/dad2.12003.Zhang Y., Cruickshanks N., Pahuski M., Yuan F., Dutta A., Schiff D., Purow B., Abounader R. Noncoding RNAs in Glioblastoma. In: De Vleeschouwer S, editor. Glioblastoma [Internet]. Brisbane (AU): Codon Publications; 2017.Zhang Y., Cruickshanks N., Pahuski M., Yuan F., Dutta A., Schiff D., Purow B., Abounader R. Noncoding RNAs in Glioblastoma. In: De Vleeschouwer S, editor. Glioblastoma [Internet]. Brisbane (AU): Codon Publications; 2017.Zorofchian S., Iqbal F., Rao M., Aung P.P., Esquenazi Y., Ballester L.Y. Circulating tumour DNA, microRNA and metabolites in cerebrospinal fuid as biomarkers for central nervous system malignancies. J Clin Pathol. 2019; 72(4): 271–80. doi: 10.1136/jclinpath-2018-205414.Zorofchian S., Iqbal F., Rao M., Aung P.P., Esquenazi Y., Ballester L.Y. Circulating tumour DNA, microRNA and metabolites in cerebrospinal fuid as biomarkers for central nervous system malignancies. J Clin Pathol. 2019; 72(4): 271–80. doi: 10.1136/jclinpath-2018-205414.Duan X., Liu D., Wang Y., Chen Z. Circular RNA hsa_circ_0074362 Promotes Glioma Cell Proliferation, Migration, and Invasion by Attenuating the Inhibition of miR-1236-3p on HOXB7 Expression. DNA Cell Biol. 2018; 37(11): 917–24. doi: 10.1089/dna.2018.4311.Duan X., Liu D., Wang Y., Chen Z. Circular RNA hsa_circ_0074362 Promotes Glioma Cell Proliferation, Migration, and Invasion by Attenuating the Inhibition of miR-1236-3p on HOXB7 Expression. DNA Cell Biol. 2018; 37(11): 917–24. doi: 10.1089/dna.2018.4311.Song X., Zhang N., Han P., Moon B.S., Lai R.K., Wang K., Lu W. Circular RNA profle in gliomas revealed by identifcation tool UROBORUS. Nucleic Acids Res. 2016; 44(9). doi: 10.1093/nar/gkw075.Song X., Zhang N., Han P., Moon B.S., Lai R.K., Wang K., Lu W. Circular RNA profle in gliomas revealed by identifcation tool UROBORUS. Nucleic Acids Res. 2016; 44(9). doi: 10.1093/nar/gkw075.Barbagallo D., Caponnetto A., Cirnigliaro M., Brex D., Barbagallo C., D’Angeli F., Morrone A., Caltabiano R., Barbagallo G.M., Ragusa M., Di Pietro C., Hansen T.B., Purrello M. CircSMARCA5 Inhibits Migration of Glioblastoma Multiforme Cells by Regulating a Molecular Axis Involving Splicing Factors SRSF1/SRSF3/PTB. Int J Mol Sci. 2018; 19(2): 480. doi: 10.3390/ijms19020480.Barbagallo D., Caponnetto A., Cirnigliaro M., Brex D., Barbagallo C., D’Angeli F., Morrone A., Caltabiano R., Barbagallo G.M., Ragusa M., Di Pietro C., Hansen T.B., Purrello M. CircSMARCA5 Inhibits Migration of Glioblastoma Multiforme Cells by Regulating a Molecular Axis Involving Splicing Factors SRSF1/SRSF3/PTB. Int J Mol Sci. 2018; 19(2): 480. doi: 10.3390/ijms19020480.Wang Y., Sui X., Zhao H., Cong L., Li Y., Xin T., Guo M., Hao W. Decreased circular RNA hsa_circ_0001649 predicts unfavorable prognosis in glioma and exerts oncogenic properties in vitro and in vivo. Gene. 2018; 676: 117–22. doi: 10.1016/j.gene.2018.07.037.Wang Y., Sui X., Zhao H., Cong L., Li Y., Xin T., Guo M., Hao W. Decreased circular RNA hsa_circ_0001649 predicts unfavorable prognosis in glioma and exerts oncogenic properties in vitro and in vivo. Gene. 2018; 676: 117–22. doi: 10.1016/j.gene.2018.07.037.Barbagallo D., Caponnetto A., Brex D., Mirabella F., Barbagallo C., Lauretta G., Morrone A., Certo F., Broggi G., Caltabiano R., Barbagallo G.M., Spina-Purrello V., Ragusa M., Di Pietro C., Hansen T.B., Purrello M. CircSMARCA5 Regulates VEGFA mRNA Splicing and Angiogenesis in Glioblastoma Multiforme Through the Binding of SRSF1. Cancers (Basel). 2019; 11(2): 194. doi: 10.3390/cancers11020194.Barbagallo D., Caponnetto A., Brex D., Mirabella F., Barbagallo C., Lauretta G., Morrone A., Certo F., Broggi G., Caltabiano R., Barbagallo G.M., Spina-Purrello V., Ragusa M., Di Pietro C., Hansen T.B., Purrello M. CircSMARCA5 Regulates VEGFA mRNA Splicing and Angiogenesis in Glioblastoma Multiforme Through the Binding of SRSF1. Cancers (Basel). 2019; 11(2): 194. doi: 10.3390/cancers11020194.Jin P., Huang Y., Zhu P., Zou Y., Shao T., Wang O. CircRNA circHIPK3 serves as a prognostic marker to promote glioma progression by regulating miR-654/IGF2BP3 signaling. Biochem Biophys Res Commun. 2018; 503(3): 1570–4. doi: 10.1016/j.bbrc.2018.07.081.Jin P., Huang Y., Zhu P., Zou Y., Shao T., Wang O. CircRNA circHIPK3 serves as a prognostic marker to promote glioma progression by regulating miR-654/IGF2BP3 signaling. Biochem Biophys Res Commun. 2018; 503(3): 1570–4. doi: 10.1016/j.bbrc.2018.07.081.Zhang M., Huang N., Yang X., Luo J., Yan S., Xiao F., Chen W., Gao X., Zhao K., Zhou H., Li Z., Ming L., Xie B., Zhang N. A novel protein encoded by the circular form of the SHPRH gene suppresses glioma tumorigenesis. Oncogene. 2018; 37(13): 1805–14. doi: 10.1038/s41388-017-0019-9.Zhang M., Huang N., Yang X., Luo J., Yan S., Xiao F., Chen W., Gao X., Zhao K., Zhou H., Li Z., Ming L., Xie B., Zhang N. A novel protein encoded by the circular form of the SHPRH gene suppresses glioma tumorigenesis. Oncogene. 2018; 37(13): 1805–14. doi: 10.1038/s41388-017-0019-9.Yang M., Li G., Fan L., Zhang G., Xu J., Zhang J. Circular RNA circ_0034642 elevates BATF3 expression and promotes cell proliferation and invasion through miR-1205 in glioma. Biochem Biophys Res Commun. 2019; 508(3): 980–5. doi: 10.1016/j.bbrc.2018.12.052.Yang M., Li G., Fan L., Zhang G., Xu J., Zhang J. Circular RNA circ_0034642 elevates BATF3 expression and promotes cell proliferation and invasion through miR-1205 in glioma. Biochem Biophys Res Commun. 2019; 508(3): 980–5. doi: 10.1016/j.bbrc.2018.12.052.Lei B., Huang Y., Zhou Z., Zhao Y., Thapa A.J., Li W., Cai W., Deng Y. Circular RNA hsa_circ_0076248 promotes oncogenesis of glioma by sponging miR-181a to modulate SIRT1 expression. J Cell Biochem. 2019; 120(4): 6698–6708. doi: 10.1002/jcb.27966.Lei B., Huang Y., Zhou Z., Zhao Y., Thapa A.J., Li W., Cai W., Deng Y. Circular RNA hsa_circ_0076248 promotes oncogenesis of glioma by sponging miR-181a to modulate SIRT1 expression. J Cell Biochem. 2019; 120(4): 6698–6708. doi: 10.1002/jcb.27966.Ding C., Yi X., Wu X., Bu X., Wang D., Wu Z., Zhang G., Gu J., Kang D. Exosome-mediated transfer of circRNA CircNFIX enhances temozolomide resistance in glioma. Cancer Lett. 2020; 479: 1–12. doi: 10.1016/j.canlet.2020.03.002.Ding C., Yi X., Wu X., Bu X., Wang D., Wu Z., Zhang G., Gu J., Kang D. Exosome-mediated transfer of circRNA CircNFIX enhances temozolomide resistance in glioma. Cancer Lett. 2020; 479: 1–12. doi: 10.1016/j.canlet.2020.03.002.DeOcesano-Pereira C., Machado R.A.C., Chudzinski-Tavassi A.M., Sogayar M.C. Emerging Roles and Potential Applications of Non-Coding RNAs in Glioblastoma. Int J Mol Sci. 2020; 21(7): 2611. doi: 10.3390/ijms21072611.DeOcesano-Pereira C., Machado R.A.C., Chudzinski-Tavassi A.M., Sogayar M.C. Emerging Roles and Potential Applications of Non-Coding RNAs in Glioblastoma. Int J Mol Sci. 2020; 21(7): 2611. doi: 10.3390/ijms21072611.Chen W., Xu X.K., Li J.L., Kong K.K., Li H., Chen C., He J., Wang F., Li P., Ge X.S., Li F.C. MALAT1 is a prognostic factor in glioblastoma multiforme and induces chemoresistance to temozolomide through suppressing miR-203 and promoting thymidylate synthase expression. Oncotarget. 2017; 8(14): 22783–99. doi: 10.18632/oncotarget.15199.Chen W., Xu X.K., Li J.L., Kong K.K., Li H., Chen C., He J., Wang F., Li P., Ge X.S., Li F.C. MALAT1 is a prognostic factor in glioblastoma multiforme and induces chemoresistance to temozolomide through suppressing miR-203 and promoting thymidylate synthase expression. Oncotarget. 2017; 8(14): 22783–99. doi: 10.18632/oncotarget.15199.Mazor G., Levin L., Picard D., Ahmadov U., Carén H., Borkhardt A., Reifenberger G., Leprivier G., Remke M., Rotblat B. The lncRNA TP73-AS1 is linked to aggressiveness in glioblastoma and promotes temozolomide resistance in glioblastoma cancer stem cells. Cell Death Dis. 2019; 10(3): 246. doi: 10.1038/s41419-019-1477-5.Mazor G., Levin L., Picard D., Ahmadov U., Carén H., Borkhardt A., Reifenberger G., Leprivier G., Remke M., Rotblat B. The lncRNA TP73-AS1 is linked to aggressiveness in glioblastoma and promotes temozolomide resistance in glioblastoma cancer stem cells. Cell Death Dis. 2019; 10(3): 246. doi: 10.1038/s41419-019-1477-5.Liu Q., Qi C., Li G., Su W. Prediction of the Outcome for Patients with Glioblastoma with lncRNA Expression Profles. Biomed Res Int. 2019. https://doi.org/10.1155/2019/5076467.Liu Q., Qi C., Li G., Su W. Prediction of the Outcome for Patients with Glioblastoma with lncRNA Expression Profles. Biomed Res Int. 2019. https://doi.org/10.1155/2019/5076467.Wang Q., Li P., Li A., Jiang W., Wang H., Wang J., Xie K. Plasma specifc miRNAs as predictive biomarkers for diagnosis and prognosis of glioma. J Exp Clin Cancer Res. 2012; 31(1): 97. doi: 10.1186/1756-9966-31-97.Wang Q., Li P., Li A., Jiang W., Wang H., Wang J., Xie K. Plasma specifc miRNAs as predictive biomarkers for diagnosis and prognosis of glioma. J Exp Clin Cancer Res. 2012; 31(1): 97. doi: 10.1186/1756-9966-31-97.Teplyuk N.M., Mollenhauer B., Gabriely G., Giese A., Kim E., Smolsky M., Kim R.Y., Saria M.G., Pastorino S., Kesari S., Krichevsky A.M. MicroRNAs in cerebrospinal fuid identify glioblastoma and metastatic brain cancers and refect disease activity. Neuro Oncol. 2012; 14(6): 689–700. doi: 10.1093/neuonc/nos074.Teplyuk N.M., Mollenhauer B., Gabriely G., Giese A., Kim E., Smolsky M., Kim R.Y., Saria M.G., Pastorino S., Kesari S., Krichevsky A.M. MicroRNAs in cerebrospinal fuid identify glioblastoma and metastatic brain cancers and refect disease activity. Neuro Oncol. 2012; 14(6): 689–700. doi: 10.1093/neuonc/nos074.Roth P., Wischhusen J., Happold C., Chandran P.A., Hofer S., Eisele G., Weller M., Keller A. A specifc miRNA signature in the peripheral blood of glioblastoma patients. J Neurochem. 2011; 118(3): 449–57. doi: 10.1111/j.1471-4159.2011.07307.x.Roth P., Wischhusen J., Happold C., Chandran P.A., Hofer S., Eisele G., Weller M., Keller A. A specifc miRNA signature in the peripheral blood of glioblastoma patients. J Neurochem. 2011; 118(3): 449–57. doi: 10.1111/j.1471-4159.2011.07307.x.Manterola L., Guruceaga E., Gállego Pérez-Larraya J., GonzálezHuarriz M., Jauregui P., Tejada S., Diez-Valle R., Segura V., Samprón N., Barrena C., Ruiz I., Agirre A., Ayuso A., Rodríguez J., González A., Xipell E., Matheu A., López de Munain A., Tuñón T., Zazpe I., García-Foncillas J., Paris S., Delattre J.Y., Alonso M.M. A small noncoding RNA signature found in exosomes of GBM patient serum as a diagnostic tool. Neuro Oncol. 2014; 16(4): 520–7. doi: 10.1093/neuonc/not218.Manterola L., Guruceaga E., Gállego Pérez-Larraya J., GonzálezHuarriz M., Jauregui P., Tejada S., Diez-Valle R., Segura V., Samprón N., Barrena C., Ruiz I., Agirre A., Ayuso A., Rodríguez J., González A., Xipell E., Matheu A., López de Munain A., Tuñón T., Zazpe I., García-Foncillas J., Paris S., Delattre J.Y., Alonso M.M. A small noncoding RNA signature found in exosomes of GBM patient serum as a diagnostic tool. Neuro Oncol. 2014; 16(4): 520–7. doi: 10.1093/neuonc/not218.Zhang Y., Ta W.W., Sun P.F., Meng Y.F., Zhao C.Z. Diagnostic and prognostic signifcance of serum miR-145-5p expression in glioblastoma. Int J Clin Exp Pathol. 2019; 12(7): 2536–43.Zhang Y., Ta W.W., Sun P.F., Meng Y.F., Zhao C.Z. Diagnostic and prognostic signifcance of serum miR-145-5p expression in glioblastoma. Int J Clin Exp Pathol. 2019; 12(7): 2536–43.Srinivasan S., Patric I.R., Somasundaram K. A ten-microRNA expression signature predicts survival in glioblastoma. PLoS One. 2011; 6(3). doi: 10.1371/journal.pone.0017438.Srinivasan S., Patric I.R., Somasundaram K. A ten-microRNA expression signature predicts survival in glioblastoma. PLoS One. 2011; 6(3). doi: 10.1371/journal.pone.0017438.Xiao Y., Zhang L., Song Z., Guo C., Zhu J., Li Z., Zhu S. Potential Diagnostic and Prognostic Value of Plasma Circulating MicroRNA-182 in Human Glioma. Med Sci Monit. 2016; 22: 855–62. doi: 10.12659/msm.897164.Xiao Y., Zhang L., Song Z., Guo C., Zhu J., Li Z., Zhu S. Potential Diagnostic and Prognostic Value of Plasma Circulating MicroRNA-182 in Human Glioma. Med Sci Monit. 2016; 22: 855–62. doi: 10.12659/msm.897164.Zhao H., Shen J., Hodges T.R., Song R., Fuller G.N., Heimberger A.B. Serum microRNA profling in patients with glioblastoma: a survival analysis. Mol Cancer. 2017; 16(1): 59. doi: 10.1186/s12943-017-0628-5.Zhao H., Shen J., Hodges T.R., Song R., Fuller G.N., Heimberger A.B. Serum microRNA profling in patients with glioblastoma: a survival analysis. Mol Cancer. 2017; 16(1): 59. doi: 10.1186/s12943-017-0628-5.Wang Z.Q., Zhang M.Y., Deng M.L., Weng N.Q., Wang H.Y., Wu S.X. Low serum level of miR-485-3p predicts poor survival in patients with glioblastoma. PLoS One. 2017; 12(9). doi: 10.1371/journal.pone.0184969.Wang Z.Q., Zhang M.Y., Deng M.L., Weng N.Q., Wang H.Y., Wu S.X. Low serum level of miR-485-3p predicts poor survival in patients with glioblastoma. PLoS One. 2017; 12(9). doi: 10.1371/journal.pone.0184969.Shi L., Zhang S., Feng K., Wu F., Wan Y., Wang Z., Zhang J., Wang Y., Yan W., Fu Z., You Y. MicroRNA-125b-2 confers human glioblastoma stem cells resistance to temozolomide through the mitochondrial pathway of apoptosis. Int J Oncol. 2012; 40(1): 119–29. doi: 10.3892/ijo.2011.1179.Shi L., Zhang S., Feng K., Wu F., Wan Y., Wang Z., Zhang J., Wang Y., Yan W., Fu Z., You Y. MicroRNA-125b-2 confers human glioblastoma stem cells resistance to temozolomide through the mitochondrial pathway of apoptosis. Int J Oncol. 2012; 40(1): 119–29. doi: 10.3892/ijo.2011.1179.Huang B.S., Luo Q.Z., Han Y., Huang D., Tang Q.P., Wu L.X. MiR-223/PAX6 Axis Regulates Glioblastoma Stem Cell Proliferation and the Chemo Resistance to TMZ via Regulating PI3K/Akt Pathway. J Cell Biochem. 2017; 118(10): 3452–61. doi: 10.1002/jcb.26003.Huang B.S., Luo Q.Z., Han Y., Huang D., Tang Q.P., Wu L.X. MiR-223/PAX6 Axis Regulates Glioblastoma Stem Cell Proliferation and the Chemo Resistance to TMZ via Regulating PI3K/Akt Pathway. J Cell Biochem. 2017; 118(10): 3452–61. doi: 10.1002/jcb.26003.Gwak H.S., Kim T.H., Jo G.H., Kim Y.J., Kwak H.J., Kim J.H., Yin J., Yoo H., Lee S.H., Park J.B. Silencing of microRNA-21 confers radio-sensitivity through inhibition of the PI3K/AKT pathway and enhancing autophagy in malignant glioma cell lines. PLoS One. 2012; 7(10). doi: 10.1371/journal.pone.0047449.Gwak H.S., Kim T.H., Jo G.H., Kim Y.J., Kwak H.J., Kim J.H., Yin J., Yoo H., Lee S.H., Park J.B. Silencing of microRNA-21 confers radio-sensitivity through inhibition of the PI3K/AKT pathway and enhancing autophagy in malignant glioma cell lines. PLoS One. 2012; 7(10). doi: 10.1371/journal.pone.0047449.Sun J., Ye L., Wang C., Li N., Wang D., Li X. MicroRNA-128 increases glioma cell radio-sensitivity by suppressing senescent evasion through oncogene Bmi-1. Int J Clin Exp Pathol. 2018; 11(3): 1423–30.Sun J., Ye L., Wang C., Li N., Wang D., Li X. MicroRNA-128 increases glioma cell radio-sensitivity by suppressing senescent evasion through oncogene Bmi-1. Int J Clin Exp Pathol. 2018; 11(3): 1423–30.Yue X., Lan F., Xia T. Hypoxic Glioma Cell-Secreted Exosomal miR-301a Activates Wnt/β-catenin Signaling and Promotes Radiation Resistance by Targeting TCEAL7. Mol Ther. 2019; 27(11): 1939–49. doi: 10.1016/j.ymthe.2019.07.011.Yue X., Lan F., Xia T. Hypoxic Glioma Cell-Secreted Exosomal miR-301a Activates Wnt/β-catenin Signaling and Promotes Radiation Resistance by Targeting TCEAL7. Mol Ther. 2019; 27(11): 1939–49. doi: 10.1016/j.ymthe.2019.07.011.Zhang Y., Ta W.W., Sun P.F., Meng Y.F., Zhao C.Z. Diagnostic and prognostic signifcance of serum miR-145-5p expression in glioblastoma. Int J Clin Exp Pathol. 2019; 12(7): 2536–43.Zhang Y., Ta W.W., Sun P.F., Meng Y.F., Zhao C.Z. Diagnostic and prognostic signifcance of serum miR-145-5p expression in glioblastoma. Int J Clin Exp Pathol. 2019; 12(7): 2536–43.Zhou Q., Liu J., Quan J., Liu W., Tan H., Li W. MicroRNAs as potential biomarkers for the diagnosis of glioma: A systematic review and meta-analysis. Cancer Sci. 2018; 109(9): 2651–9. doi: 10.1111/cas.13714.Zhou Q., Liu J., Quan J., Liu W., Tan H., Li W. MicroRNAs as potential biomarkers for the diagnosis of glioma: A systematic review and meta-analysis. Cancer Sci. 2018; 109(9): 2651–9. doi: 10.1111/cas.13714.Yue X., Lan F., Hu M., Pan Q., Wang Q., Wang J. Downregulation of serum microRNA-205 as a potential diagnostic and prognostic biomarker for human glioma. J Neurosurg. 2016; 124(1): 122–8. doi: 10.3171/2015.1.JNS141577.Yue X., Lan F., Hu M., Pan Q., Wang Q., Wang J. Downregulation of serum microRNA-205 as a potential diagnostic and prognostic biomarker for human glioma. J Neurosurg. 2016; 124(1): 122–8. doi: 10.3171/2015.1.JNS141577.Yang C., Wang C., Chen X., Chen S., Zhang Y., Zhi F., Wang J., Li L., Zhou X., Li N., Pan H., Zhang J., Zen K., Zhang C.Y., Zhang C. Identifcation of seven serum microRNAs from a genome-wide serum microRNA expression profle as potential noninvasive biomarkers for malignant astrocytomas. Int J Cancer. 2013; 132(1): 116–27. doi: 10.1002/ijc.27657.Yang C., Wang C., Chen X., Chen S., Zhang Y., Zhi F., Wang J., Li L., Zhou X., Li N., Pan H., Zhang J., Zen K., Zhang C.Y., Zhang C. Identifcation of seven serum microRNAs from a genome-wide serum microRNA expression profle as potential noninvasive biomarkers for malignant astrocytomas. Int J Cancer. 2013; 132(1): 116–27. doi: 10.1002/ijc.27657.Shao N., Wang L., Xue L., Wang R., Lan Q. Plasma miR-454-3p as a potential prognostic indicator in human glioma. Neurol Sci. 2015; 36(2): 309–13. doi: 10.1007/s10072-014-1938-7.Shao N., Wang L., Xue L., Wang R., Lan Q. Plasma miR-454-3p as a potential prognostic indicator in human glioma. Neurol Sci. 2015; 36(2): 309–13. doi: 10.1007/s10072-014-1938-7.Sun J., Liao K., Wu X., Huang J., Zhang S., Lu X. Serum microRNA-128 as a biomarker for diagnosis of glioma. Int J Clin Exp Med. 2015; 8(1): 456–63.Sun J., Liao K., Wu X., Huang J., Zhang S., Lu X. Serum microRNA-128 as a biomarker for diagnosis of glioma. Int J Clin Exp Med. 2015; 8(1): 456–63.Tang H., Liu Q., Liu X., Ye F., Xie X., Xie X., Wu M. Plasma miR185 as a predictive biomarker for prognosis of malignant glioma. J Cancer Res Ther. 2015; 11(3): 630–4. doi: 10.4103/0973-1482.146121.Tang H., Liu Q., Liu X., Ye F., Xie X., Xie X., Wu M. Plasma miR185 as a predictive biomarker for prognosis of malignant glioma. J Cancer Res Ther. 2015; 11(3): 630–4. doi: 10.4103/0973-1482.146121.ParvizHamidi M., Haddad G., Ostadrahimi S., Ostadrahimi N., Sadeghi S., Fayaz S., Fard-Esfahani P. Circulating miR-26a and miR-21 as biomarkers for glioblastoma multiform. Biotechnol Appl Biochem. 2019; 66(2): 261–5. doi: 10.1002/bab.1707.ParvizHamidi M., Haddad G., Ostadrahimi S., Ostadrahimi N., Sadeghi S., Fayaz S., Fard-Esfahani P. Circulating miR-26a and miR-21 as biomarkers for glioblastoma multiform. Biotechnol Appl Biochem. 2019; 66(2): 261–5. doi: 10.1002/bab.1707.Wang J., Che F., Zhang J., Zhang M., Xiao S., Liu Y., Zhou L., Su Q., You C., Lu Y., Heng X. Diagnostic and Prognostic Potential of Serum Cell-Free microRNA-214 in Glioma. World Neurosurg. 2019; 125: 1217–25. doi: 10.1016/j.wneu.2019.02.009.Wang J., Che F., Zhang J., Zhang M., Xiao S., Liu Y., Zhou L., Su Q., You C., Lu Y., Heng X. Diagnostic and Prognostic Potential of Serum Cell-Free microRNA-214 in Glioma. World Neurosurg. 2019; 125: 1217–25. doi: 10.1016/j.wneu.2019.02.009.Akers J.C., Hua W., Li H., Ramakrishnan V., Yang Z., Quan K., Zhu W., Li J., Figueroa J., Hirshman B.R., Miller B., Piccioni D., Ringel F., Komotar R., Messer K., Galasko D.R., Hochberg F., Mao Y., Carter B.S., Chen C.C. A cerebrospinal fuid microRNA signature as biomarker for glioblastoma. Oncotarget. 2017; 8(40): 68769–79. doi: 10.18632/oncotarget.18332.Akers J.C., Hua W., Li H., Ramakrishnan V., Yang Z., Quan K., Zhu W., Li J., Figueroa J., Hirshman B.R., Miller B., Piccioni D., Ringel F., Komotar R., Messer K., Galasko D.R., Hochberg F., Mao Y., Carter B.S., Chen C.C. A cerebrospinal fuid microRNA signature as biomarker for glioblastoma. Oncotarget. 2017; 8(40): 68769–79. doi: 10.18632/oncotarget.18332.

The authors declare that there are no conflicts of interest present.